

# Julius Wehrle

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/724636/publications.pdf>

Version: 2024-02-01

21  
papers

506  
citations

840585

11  
h-index

677027

22  
g-index

22  
all docs

22  
docs citations

22  
times ranked

1076  
citing authors

#	ARTICLE	IF	CITATIONS
1	Early assessment of circulating tumor DNA after curative-intent resection predicts tumor recurrence in early-stage and locally advanced non-small-cell lung cancer. <i>Molecular Oncology</i> , 2022, 16, 527-537.	2.1	42
2	Targeted next-generation sequencing of circulating free DNA enables non-invasive tumor detection in myxoid liposarcomas. <i>Molecular Cancer</i> , 2022, 21, 50.	7.9	2
3	Genotyping of Circulating Free DNA Enables Monitoring of Tumor Dynamics in Synovial Sarcomas. <i>Cancers</i> , 2022, 14, 2078.	1.7	6
4	Predicting persistence of atopic dermatitis in children using clinical attributes and serum proteins. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1158-1172.	2.7	16
5	Bisulfite-free epigenomics and genomics of single cells through methylation-sensitive restriction. <i>Communications Biology</i> , 2021, 4, 153.	2.0	17
6	Transitioning the Molecular Tumor Board from Proof of Concept to Clinical Routine: A German Single-Center Analysis. <i>Cancers</i> , 2021, 13, 1151.	1.7	27
7	Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes. <i>Nature Medicine</i> , 2021, 27, 1806-1817.	15.2	79
8	Stringent Base Specific and Optimization-Free Multiplex Mediator Probe ddPCR for the Quantification of Point Mutations in Circulating Tumor DNA. <i>Cancers</i> , 2021, 13, 5742.	1.7	3
9	Clonal hematopoiesis of indeterminate potential in older patients having received an allogeneic stem cell transplantation from young donors. <i>Bone Marrow Transplantation</i> , 2020, 55, 665-668.	1.3	7
10	Prevalence and characteristics of myeloproliferative neoplasms with concomitant monoclonal gammopathy. <i>Leukemia Research</i> , 2020, 98, 106454.	0.4	8
11	Personalized Treatment Selection and Disease Monitoring Using Circulating Tumor DNA Profiling in Real-World Cancer Patient Management. <i>Diagnostics</i> , 2020, 10, 550.	1.3	8
12	Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia. <i>Annals of Hematology</i> , 2020, 99, 1551-1560.	0.8	15
13	Circulating Tumor DNA Allows Early Treatment Monitoring in BRAF- and NRAS-Mutant Malignant Melanoma. <i>JCO Precision Oncology</i> , 2020, 4, 20-31.	1.5	19
14	The transcription factor NFE2 enhances expression of the hematopoietic master regulators SCL/TAL1 and GATA2. <i>Experimental Hematology</i> , 2020, 87, 42-47.e1.	0.2	4
15	Oncogenic JAK2 <sup>V617F</sup> causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. <i>Science Translational Medicine</i> , 2018, 10, .	5.8	166
16	Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience. <i>JCO Precision Oncology</i> , 2018, 2, 1-16.	1.5	41
17	Gene mutations and clonal architecture in myelodysplastic syndromes and changes upon progression to acute myeloid leukaemia and under treatment. <i>British Journal of Haematology</i> , 2018, 182, 830-842.	1.2	16
18	Ponatinib: A Third-Generation Inhibitor for the Treatment of CML. <i>Recent Results in Cancer Research</i> , 2018, 212, 109-118.	1.8	10

#	ARTICLE	IF	CITATIONS
19	Monosomy 7 As the Initial Hit Followed By Sequential Acquisition of SETBP1 and ASXL1 Driver Mutations in Childhood Myelodysplastic Syndromes. <i>Blood</i> , 2018, 132, 105-105.	0.6	2
20	The oligodendrocyte lineage transcription factor 2 (OLIG2) is epigenetically regulated in acute myeloid leukemia. <i>Experimental Hematology</i> , 2017, 55, 76-85.e3.	0.2	3
21	A novel role for nuclear factor-erythroid 2 in erythroid maturation by modulation of mitochondrial autophagy. <i>Haematologica</i> , 2016, 101, 1054-1064.	1.7	13